
Cefika S 250mg/125mg Injection
Marketer
Stadchem Of India
Salt Composition
Ceftriaxone (250mg) + Sulbactam (125mg)
Overview Cefika S 250mg/125mg Injection
Cefika S Injection (250mg/125mg) combines medications to combat diverse bacterial infections. Its mechanism inhibits microbial proliferation, curbing infection spread. Administration must be solely under a doctor's guidance; strict adherence to the prescribed schedule is crucial. Complete the full course, regardless of symptom improvement; premature cessation may compromise efficacy. Potential side effects include nausea, vomiting, diarrhea, and dyspepsia. Report worsening side effects immediately to your physician. Seek urgent medical attention for allergic reactions (e.g., rashes, itching, swelling, respiratory distress). Inform your doctor about all current medications, including those for pre-existing conditions. Pregnant or lactating individuals should consult their physician before use. Alcohol consumption should be avoided due to potential increased drowsiness. While generally not impairing driving ability, avoid driving if drowsiness or dizziness occurs. Adequate rest, a balanced diet, and sufficient hydration are recommended for optimal recovery. Your doctor may order lab tests and diagnostics to monitor the medication's effects.
Primary Ingredients of Cefika S 250mg/125mg Injection
The provided text is "undefined," which has no meaning to rephrase. A rephrased version cannot be provided.
Uses of Cefika S 250mg/125mg Injection
Infections caused by bacteria
Major Benefits of Cefika S 250mg/125mg Injection:
This medication will be administered by your physician or registered nurse; please do not attempt self-medication.
Common Side effects of Cefika S 250mg/125mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Cefika S 250mg/125mg Injection:
This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
How Cefika S 250mg/125mg Injection works:
Ceftriaxone and Sulbactam, combined as Cefika S 250 mg/125 mg Injection, offer a dual-action approach to bacterial infections. Ceftriaxone, a potent antibiotic, disrupts bacterial cell wall synthesis, hindering their ability to survive. Sulbactam, a beta-lactamase inhibitor, counters bacterial defenses, thus boosting Ceftriaxone's effectiveness.
SAFETY ADVICE
AlcoholSAFE
Ingestion of alcohol alongside Cefika S 250 mg/125 mg Injection poses no known adverse reactions.
PregnancySAFE IF PRESCRIBED
Cefika S 250 mg/125 mg Injection is typically deemed safe for use in pregnancy. Preclinical trials in animals revealed minimal or no harmful effects on fetal development; nevertheless, clinical data from human studies remain scarce.
Breast feedingCAUTION
Administering Cefika S 250 mg/125 mg Injection to breastfeeding mothers requires careful consideration. Discontinue breastfeeding for the duration of maternal treatment and until the medication is fully cleared from the mother's system.
DrivingUNSAFE
Administering Cefika S 250 mg/125 mg Injection could induce drowsiness, visual disturbances, or dizziness. Refrain from operating a vehicle if such effects manifest.
KidneyCONSULT YOUR DOCTOR
Data regarding Cefika S 250 mg/125 mg Injection use in individuals with renal impairment is scarce. Seek medical advice from your physician.
LiverCAUTION
Exercise caution when administering Cefika S 250 mg/125 mg Injection to individuals with severe hepatic impairment; dosage modification may be necessary. Consult a physician for guidance. Dosage alteration for Cefika S 250 mg/125 mg Injection is unnecessary for patients exhibiting mild to moderate liver dysfunction.
What if you forget to take Cefika S 250mg/125mg Injection :
Should you forget a dose of Cefika S 250 mg/125 mg Injection, seek medical advice.
Facts to Know About Cefika S 250mg/125mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Anti-infective agents |
